Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer

Adult Science Carcinoma, Ovarian Epithelial MicroRNAs/biosynthesis Neoplasm/biosynthesis Disease-Free Survival Databases Ovarian Neoplasms/genetics 03 medical and health sciences 0302 clinical medicine 80 and over Humans RNA, Neoplasm Aged Oligonucleotide Array Sequence Analysis Aged, 80 and over Ovarian Neoplasms Nucleic Acid Gene Expression Profiling Carcinoma Q R Middle Aged Ovarian Epithelial/genetics 3. Good health Survival Rate Carcinoma, Ovarian Epithelial/genetics MicroRNAs RNA Medicine Female Databases, Nucleic Acid RNA, Neoplasm/biosynthesis Research Article
DOI: 10.1371/journal.pone.0207319 Publication Date: 2018-11-26T19:39:19Z
ABSTRACT
Background Ovarian cancer is the leading cause of death by gynecologic cancers in Western world. The aim study was to identify microRNAs (miRNAs) associated with prognosis and/or resistance chemotherapy among patients epithelial ovarian cancer. Methods Using information from Pelvic Mass Study we identified a cohort women Tumor tissues were then collected and analyzed global miRNA microarrays. MiRNA profiling linked survival time progression using Cox proportional-hazards regression models. Logistic models used for analysis chemotherapy. Our results validated external datasets retrieved NCBI Gene Expression Omnibus database. Results A total 197 included microarray analysis. In multivariate analyses number miRNAs significantly correlated overall (miR-1183 (HR: 1.42, 95% CI:1.17–1.74, p = 0.0005), miR-126-3p 1.38, CI:1.11–1.71, 0.0036), (miR-139-3p 1.48, CI: 1.13–1.94, 0.0047), miR-802 0.48, 0.29–0.78, 0.0035)), free (miR-23a-5p (HR:1.32, CI:1.09–1.61, 0.004), miR-23a-3p (HR:1.70, CI:1.15–2.51, 0.0074), 0.29–0.80, 0.0048)), (miR-1234 0.26, 0.11–0.64, 0.003)). few our training cohort, cohorts similar results. Conclusion Eight as significant predictors survival, progression, resistance. these datasets. Inter-platform inter-laboratory variations may have influence on ability compare reproduce use potential markers relapse warrants further investigation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (63)
CITATIONS (32)